Effects of incretin-based therapies on neurocognitive function in humans: A systematic review of the literature.
systematic_review · Level I
Where this comes from
- Record sourced from PubMed, PMID 28732654.
- Also identified by DOI 10.1016/j.pcd.2017.06.009.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We performed a PRISMA systematic review of incretin-based therapies and effects on neurocognitive function in humans. There was observational evidence to support dipeptidyl peptidase-IV inhibitors in improving cognition, whilst glucagon-like peptide-1 had positive effects on cerebral glucose metabolism. Powered clinical trials are now needed in patients with- and without diabetes.
Medical subject headings
- Brain
- Cognition
- Cognition Disorders
- Dipeptidyl Peptidase 4
- Dipeptidyl-Peptidase IV Inhibitors
- Glucose
- Incretins
- Glucagon-Like Peptide-1 Receptor Agonists